The Architecture of Universal Medicine: Platform Technologies, Artificial Intelligence, and Global Regulatory Harmonization in the Modern Bio-Economy

Introduction: The Evolution of the Universal Panacea

Historically, the concept of a universal medicine—a "panacea" capable of curing all maladies and prolonging life indefinitely—was relegated to the realm of mythology and alchemical pursuit.1 From the Greek goddess Panacea, daughter of Asclepius, to the philosopher's stone sought by seventeenth-century figures like Paracelsus and Van Helmont (who famously pursued an "alkahest" or universal solvent), the search for a singular, omnipotent chemical compound has long driven human scientific curiosity.1 In the modern era, the biological reality of disease complexity, genetic variation, and rapid pathogen mutation rendered the idea of a single "cure-all" molecule scientifically implausible. Consequently, the prevailing paradigm of the late twentieth and early twenty-first centuries shifted heavily toward precision medicine, multi-omics, and individualized therapies tailored to specific genomic profiles.3

However, the scientific landscape in 2026 demonstrates a profound paradigm shift. The pursuit of a global universal medicine has been resurrected, not as a singular chemical entity, but as a matrix of highly adaptable, broad-spectrum "platform technologies".6 It is important to distinguish this rigorous scientific endeavor from esoteric or pseudoscientific appropriations of the term, such as the Australian cult operating under the name "Universal Medicine," which has faced extensive legal scrutiny and Supreme Court defamation rulings regarding fraudulent healing claims and abusive practices.9 In contrast to such doctrines, the modern biomedical definition of a universal medicine encompasses highly engineered therapeutics and prophylactic agents designed to target highly conserved biological mechanisms across diverse pathogen families, or to fundamentally reprogram the host immune response.6 Furthermore, initiatives like the Ayurveda-Biology project have sought to elevate traditional holistic systems to universal medicine status through modern scientific validation, demonstrating a global cultural drive toward comprehensive healthcare solutions.16

This exhaustive report examines the biological, computational, and regulatory feasibility of creating and deploying a global universal medicine. It explores the latest clinical and preclinical breakthroughs in broad-spectrum antivirals, host-directed therapies, and universal mucosal vaccines.6 Furthermore, it analyzes the indispensable role of artificial intelligence in overcoming the limitations of multi-target drug discovery, the transformation of pharmacological research through in silico virtual populations, and the decentralized digital infrastructure necessary to finance these innovations.13 Finally, the report assesses the geopolitical and regulatory gauntlet that governs the equitable global distribution of these medical countermeasures, focusing on international harmonization efforts and the ongoing negotiations surrounding the World Health Organization (WHO) Pandemic Agreement.13

The Biological Feasibility of Universal Therapeutics: Overcoming the Lock-and-Key Paradigm

The fundamental limitation of the traditional "one drug, one target" or "lock and key" paradigm is its vulnerability to biological adaptation and network redundancy.22 Viruses mutate surface antigens to evade immune recognition, while bacteria develop antimicrobial resistance (AMR) through rapid evolutionary pressure, rendering highly specific drugs obsolete.6 To achieve universal efficacy, modern therapeutics must bypass pathogen-specific surface variations. This requires intentionally designing molecules that interact simultaneously with multiple biological targets to treat multifactorial diseases—a strategy known as Multi-Target Drug Discovery (MTDD).22

While MTDD holds immense promise, it operates on a delicate biological boundary regarding compound promiscuity. A compound's ability to bind to multiple targets is essential for polypharmacology, yet unintended drug promiscuity is the primary driver of off-target side effects and clinical toxicity.25 Analyses of vast compound databases reveal that binding site promiscuity is heavily influenced by physicochemical parameters, predominantly lipophilicity (estimated by the partition coefficient, ) and basic character.26 Highly promiscuous binding pockets—which represent approximately eighty percent of druggable sites in the Mother Of All Databases—tend to be large and hydrophobic, with high sulfur atom and aliphatic residue frequencies.28 Consequently, these sites accommodate ligands that are large, rigid, and weakly hydrophilic.28 Conversely, selective sites require highly adaptable, small, and hydrophilic ligands.28 The challenge of designing a universal medicine lies in balancing these physicochemical properties to achieve broad therapeutic action without triggering widespread systemic toxicity.26

Broad-Spectrum Antivirals and Apoptosis Induction

The development of broad-spectrum antivirals represents a cornerstone in the pursuit of universal medicine, specifically designed to circumvent the mutational escape of viruses. A pioneering approach in this domain is the Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) technology.17 Unlike traditional antivirals that target specific viral enzymes or structural proteins, DRACO exploits a universal hallmark of viral replication: the presence of long viral dsRNA, which is virtually absent in healthy mammalian cells.17

DRACO molecules are engineered to selectively bind to viral dsRNA and subsequently trigger rapid apoptosis (programmed cell death) exclusively in the infected cells, terminating the viral replication cycle while leaving uninfected tissue unharmed.17 Initial preclinical evaluations demonstrated that DRACO exhibited broad-spectrum efficacy in vitro against a diverse array of fifteen infectious agents, including the dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, rhinovirus, and H1N1 influenza.17 Although the original MIT-led research program moved to the Draper Laboratory in 2014 and subsequently stalled due to a lack of traditional funding, the underlying technology has been revitalized by independent researchers and startup ecosystems.17 By 2026, subsequent derivatives, such as the VTose platform developed by the New Zealand biotechnology firm Kimer Med, have refined the mechanism of action to bypass advanced viral defenses.17 Kimer Med reported achieving perfect positive results in tests against clinically relevant viruses, offering a highly scalable, modular platform against both known viral families and emerging "Disease X" pandemic threats.17 Concurrently, other novel pathways, such as the mechano-antiviral response system (MARS) mediated by Piezo1, are being identified as broad-spectrum innate resistance mechanisms against pathogens like enterovirus D68 (EV-D68).34

Similarly, advances in synthetic carbohydrate receptors (SCRs) offer another vector for broad-spectrum antiviral action. Researchers at the City University of New York (CUNY) Advanced Science Research Center have developed SCRs capable of binding to conserved N-glycans present on the viral envelope of numerous unrelated viral families.35 By screening dozens of synthetic receptors, researchers identified compounds that effectively block virus binding and fusion across a wide spectrum of pathogens, providing a first line of defense that does not require prior identification of the specific infectious agent and securing funding from the NIH and the Department of Defense.35

The Transition to Host-Directed Therapies (HDTs)

Recognizing that pathogen-directed therapies inevitably drive resistance, there is an industry-wide pivot toward Host-Directed Therapies (HDTs).37 HDTs operate on the principle of manipulating the host's cellular machinery and immune pathways rather than attacking the pathogen directly.38 Because the host's genetic and proteomic architecture mutates at an exponentially slower rate than microbial genomes, HDTs are significantly less prone to generating antimicrobial or antiviral resistance, making them ideal candidates for universal application.15

HDTs aim to augment the host's natural immune clearance mechanisms or deny pathogens the cellular resources required for intracellular survival and replication.38 For instance, certain cellular kinases, while non-essential for host survival, are absolutely critical for the replication cycle of various viruses. Small molecule kinase inhibitors can therefore act as broad-spectrum antiviral agents by shutting down the host pathways exploited by the pathogen.40 In the context of bacterial infections, such as those caused by Mycobacterium tuberculosis and its frequent coinfection with HIV, HDTs utilizing specific protease inhibitors (like saquinavir and cystatins) are being evaluated to control intracellular persistence.41 Furthermore, modulating pathways involving STING (Stimulator of Interferon Genes), itaconate, and pyroptosis allows for the bespoke augmentation or suppression of the host inflammatory response.15 This adaptability is crucial because the disease profile often dictates whether the patient requires aggressive pathogen clearance during early infection or the mitigation of tissue-damaging cytokine storms during late-stage critical care.15 Research funding, such as the Grand Challenges initiatives, is also expanding HDTs to target complex inflammatory conditions, including placental and gut inflammation.42

Confronting Antimicrobial Resistance (AMR)

The necessity for broad-spectrum therapeutics is most acute in the context of the global antimicrobial resistance (AMR) crisis. AMR infections currently cause an estimated 1.3 million deaths globally each year, a figure projected by the United Nations to rise to 10 million annual deaths by 2050, rivaling cancer as a leading cause of mortality.23 The World Health Organization (WHO) has designated AMR as one of the top ten global public health threats, noting that one in six bacterial infections worldwide is now antibiotic-resistant.23

Despite a challenging economic landscape characterized by high-risk and low-reward R&D that has forced many large pharmaceutical companies out of antibiotic development, significant breakthroughs are occurring.23 For the first time in over half a century, a entirely new class of antibiotics is moving into human trials. Developed jointly by Roche and Harvard University, the novel antibiotic zosurabalpin is designed specifically to tackle carbapenem-resistant Acinetobacter baumannii (CRAB), a superbug considered an urgent threat by the CDC that causes invasive pneumonia and sepsis in hospital settings.23 Zosurabalpin relies on a novel mode of action that bacteria have not yet developed resistance against.23

Simultaneously, the FDA has approved new oral treatment options, including zoliflodacin and gepotidacin, which target uncomplicated gonorrhea and urinary tract infections, respectively.44 To further accelerate the discovery of broad-spectrum antibacterials, international consortiums, including the Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation, launched the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) award.43 This initiative provided over $1.5 million to researchers at the University of Connecticut to discover new broad-spectrum antibiotics targeting Gram-negative bacteria such as Klebsiella, focusing on mechanisms that disrupt the cross-linking of protein-glycan molecules in the bacterial outer membrane.43

Broad-Spectrum Monoclonal Antibodies and Universal Antivenoms

The concept of universal application extends beyond infectious diseases into the realm of envenomation and acute toxinology. Traditional antivenoms are notoriously species-specific, requiring the precise identification of the biting snake, and are typically produced using equine antibodies that carry high risks of severe adverse immune reactions, such as serum sickness, in humans.46 Venomous snakes kill as many as 138,000 people annually, highlighting the urgent need for a safer, universal therapeutic.46

Recent breakthroughs have established the feasibility of a universal antivenom capable of neutralizing venom from diverse, medically relevant snake species across the globe.46 Utilizing a synthetic human antibody library, researchers at Scripps Research and the International AIDS Vaccine Initiative (IAVI) successfully isolated and developed a laboratory-made antibody that neutralizes long-chain three-finger -neurotoxins.47 Structural analysis confirmed that this antibody mimics the receptor-toxin interaction, blocking the toxin from binding to the human nicotinic acetylcholine receptor in vitro and protecting animal models from lethal venom challenges.47 Because these are humanized antibodies produced via genetically modified cells, they eliminate the severe side effects associated with horse-derived serums and offer a highly potent, scalable, broad-spectrum therapeutic for global deployment.46

Similar efforts in virology have yielded broad-spectrum monoclonal antibodies targeting conserved epitopes. For instance, the investigational antibody VMS063 is designed to lock the trimeric measles Fusion (F) protein into a pre-fusion configuration, preventing cell entry and functioning as a potential precision therapy and passive prophylaxis.49 In the respiratory domain, antibodies such as clesrovimab target site IV of the RSV pre-fusion F protein 50, while researchers at the Fred Hutchinson Cancer Center have developed the 4F11 antibody to broadly neutralize human metapneumovirus (HMPV).51 HMPV causes an estimated 14 million serious lung infections annually in children under five and poses severe risks to immunocompromised individuals; the discovery of highly potent monoclonal antibodies targeting conserved vulnerability sites represents a critical advancement in broad-spectrum respiratory protection.51

The Universal Vaccine Paradigm: Redefining Immunological Memory

Perhaps the most tangible manifestation of a global universal medicine is the rapid evolution of vaccine technology from strain-specific inoculations to broad-spectrum, pathogen-agnostic platforms.6 For over two centuries, since Edward Jenner's use of cowpox to inoculate against smallpox, vaccinology has relied fundamentally on "antigen specificity"—exposing the adaptive immune system to a specific pathogen or viral subunit to train it for future encounters.6 The inherent flaw in this paradigm is that rapidly mutating respiratory viruses, such as influenza and coronaviruses, continuously alter their surface antigens, requiring constant vaccine reformulation, annual administration, and resulting in varying efficacy rates.6

The Stanford Universal Nasal Spray Mechanism

In February 2026, researchers at Stanford Medicine published findings in the journal Science detailing a groundbreaking intranasal vaccine formulation that challenges the foundational doctrines of immunology by targeting the innate, rather than exclusively the adaptive, immune system.6 The innate immune system consists of non-specific "generalist" cells—such as macrophages, neutrophils, and dendritic cells—that rapidly attack a wide variety of foreign invaders.6 Historically, innate immune activation was viewed as a transient response, lasting only a few days.6

The Stanford vaccine (provisionally identified as GLA-3M-052-LS+OVA) utilizes a novel "infection-mimicking" design.56 It incorporates Toll-like receptor (TLR) 4 and TLR7/8 agonists to stimulate innate immune sensors, combined with ovalbumin (OVA), a harmless egg protein acting as a model antigen.56 This specific combination triggers a localized immune response that draws T cells into the mucosal surfaces of the lungs. Building on earlier findings related to the BCG tuberculosis vaccine, researchers discovered that these lung-homing T cells continuously secrete cytokines, effectively keeping the innate immune system in a prolonged state of high alert for several months.55

The resulting protective mechanism is described as a "double whammy".6 First, the heightened innate response acts as an immediate, broad-spectrum shield that has been shown in murine models to lower lung viral titers of SARS-CoV-2 by approximately 700-fold, enabling survival with minimal morbidity.6 Second, this primed mucosal environment significantly accelerates the adaptive immune response, mobilizing virus-specific T cells and antibodies in as little as three days post-exposure, compared to the standard two weeks required in unvaccinated subjects.6 Because the vaccine relies on broad immune activation rather than specific antigen recognition, it has demonstrated robust protection against a vast spectrum of respiratory threats, including diverse coronaviruses, influenza, antibiotic-resistant hospital bacteria (Staphylococcus aureus and Acinetobacter baumannii), and even common allergens like house dust mites.6 While currently moving toward human Phase I safety trials, the lead researchers estimate that a two-dose intranasal regimen could be available to the public within five to seven years, representing the closest biomedical realization of a universal prophylactic.6

Genomic Approaches: Universal Flu and Pan-Coronavirus Developments

Parallel to the innate immune approach, major public health initiatives and biotech firms are pursuing universal vaccines through structural genomics and novel inactivation platforms. The U.S. National Institutes of Health (NIH) and the Department of Health and Human Services (HHS) launched the "Generation Gold Standard" platform.58 This initiative utilizes beta-propiolactone (BPL)-inactivated, whole-virus platforms (such as the intranasal candidate BPL-1357 and the coronavirus candidate BPL-24910).58 Unlike traditional split-virus or highly targeted mRNA vaccines, BPL inactivation preserves the structural integrity of the virus while eliminating infectivity. This exposes the immune system to a broader array of conserved viral proteins, inducing robust, long-lasting B and T cell responses across diverse viral families.60 This platform specifically targets pandemic-prone agents, including H5N1 avian influenza, SARS-CoV-1, SARS-CoV-2, and MERS-CoV, with human clinical trials scheduled through 2026 and FDA approval targeted for 2029.58

Furthermore, the global R&D pipeline tracks hundreds of next-generation candidates through databases like the Universal Influenza Vaccine Technology Landscape managed by CIDRAP.62 As of early 2026, developers are actively advancing multivalent mRNA-LNP (lipid nanoparticle) technologies and recombinant virus-like particles (VLPs) to target highly conserved regions, such as the influenza hemagglutinin stalk or the nucleocapsid, which are significantly less susceptible to mutation than the receptor-binding domains.62 Companies like Centivax are advancing universal immunity platforms that focus antibodies and cellular immunity against conserved sites of highly diverse pathogens, supported by grants from the NIH, the Department of Defense, and the Bill & Melinda Gates Foundation.65 Leyden Laboratories has also demonstrated proof-of-concept in non-human primates for a pan-influenza nasal spray (PanFlu) that delivers broadly neutralizing antibodies (CR9114) directly to the nasal mucosa, offering immediate protection at the portal of viral entry.66

Next-Generation Oncology: Universal Cancer Vaccines and Radiotherapy

The concept of a universal medicine also profoundly extends into oncology. While cancer is notoriously heterogeneous, researchers are developing universal, off-the-shelf mRNA cancer vaccines designed to act synergistically with existing immune checkpoint inhibitors.67 By utilizing lipid nanoparticles to deliver mRNA that stimulates the expression of specific proteins—such as PD-L1—directly inside the tumor microenvironment, these vaccines effectively "wake up" the immune system.67 This non-specific immune mobilization revs up the body to attack treatment-resistant tumors as if it were fighting a viral infection, offering an alternative to harsh chemotherapies and demonstrating profound efficacy when combined with existing immunotherapies.67

Clinical validation of this approach is accelerating. Analyses of over 1,000 patient records at the University of Texas MD Anderson Cancer Center and the University of Florida revealed that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine shortly after starting immunotherapy lived significantly longer, underscoring the potent immune-priming effects of mRNA technology.68 Concurrently, specific therapeutic mRNA cancer vaccines are achieving unprecedented milestones. The KEYNOTE-942 Phase III trial evaluating a personalized mRNA vaccine in combination with immunotherapy for high-risk melanoma achieved a remarkable 62 percent reduction in the risk of distant metastasis or death.71 Driven by such successes, the cancer vaccine market is projected to reach $5-7 billion by 2030.71

Institutional efforts are further expanding the pipeline. The Cancer Vaccine Institute (CVI) at UW Medicine is advancing DNA vaccines that encode several cancer-associated proteins known to drive tumor growth in breast, ovarian, lung, colon, prostate, and bladder cancers.72 Once activated, vaccine-generated immune cells circulate throughout the body to seek out cancer cells, providing long-term protection against recurrence.72 Similarly, prophylactic initiatives like LungVax, backed by Cancer Research UK, are entering trials targeting early-stage lung cancer signals in thousands of high-risk participants.73 Additionally, researchers at UCLA are demonstrating that targeting specific drivers, such as the KRAS-G12D mutation, can significantly boost tumor immune recognition in pancreatic cancer models.74

The ARPA-H 1-CURE Program and Advanced Radiotherapy

In a complementary technological leap, the Advanced Research Projects Agency for Health (ARPA-H) initiated the 1-CURE (One Comprehensive Universal Radiotherapy for Everyone) program in early 2026.75 The ambitious goal is to create a single, fast, low-cost intervention effective against all cancer types, including metastatic and pediatric cancers.75

The 1-CURE framework integrates three advanced technologies to overcome the limitations of traditional radiotherapy, which typically requires weeks of grueling appointments. The core of the program is FLASH Radiotherapy (FLASH-RT), a method that delivers an ultra-high dose of radiation in less than one second, causing significantly less damage to surrounding healthy tissue.75 This is combined with Smart Radiotherapy Biomaterials (SRBs)—multifunctional materials designed to guide the treatment and deliver sustained immune-enhancing agents directly to the tumor.75 Finally, an AI-driven Abscopal Treatment Planning System (ATPS) synergizes these elements.75 The procedure exposes tumor markers via FLASH-RT while the immune-boosting nanomaterials train the immune system to eliminate both local and distant metastatic tumors, creating a systemic abscopal effect that prevents recurrence through a universally applicable methodology.75

Artificial Intelligence, Deep Generative Modeling, and Protein Design

The sheer biological complexity of designing universal therapeutics, balancing multi-target efficacy with low promiscuity toxicity, requires computational capabilities that surpass human intuition. Consequently, the pharmaceutical industry is aggressively adopting deep generative AI models.18 These algorithms provide scalable platforms for the de novo generation of small molecules, utilizing self-improving learning systems that iteratively refine molecular candidates based on high-throughput screening feedback.18 By tightly controlling physicochemical properties during optimization, AI enables the design of drugs that were previously considered "undruggable".18

The year 2026 marks a critical inflection point where AI-native biotechs are proving clinical viability. Insilico Medicine achieved a landmark milestone with the first AI-designed drug targeting an AI-discovered disease target demonstrating efficacy in human trials.77 Utilizing their Pharma.AI platform (combining PandaOmics, Chemistry42, and inClinico), the company developed a therapeutic for idiopathic pulmonary fibrosis (IPF).77 In a Phase IIa trial, the highest dose cohort showed a mean improvement of 98.4 mL in forced vital capacity (FVC) from baseline, compared to a 62.3 mL decline in the placebo group—a profound treatment differential of approximately 160 mL.77

Other AI-native firms are securing massive capital to advance broad-spectrum pipelines. Earendil Labs recently raised $787 million to scale its AI-designed biologics in immunology and oncology, expanding partnerships with major pharmaceutical entities.76 Decoy Therapeutics is pioneering Designable Multi-Antivirals (DMAVs) through its IMP3ACT platform, engineering single, adaptable drugs designed to target shared viral mechanisms across multiple respiratory pathogens.78

Protein Design and Programmable Small Molecule Biosynthesis

The predictive power of large AI models, exemplified by AlphaFold2, has transformed computational biology from merely predicting existing biological structures to the de novo design of entirely new proteins.79 At the University of Washington's Institute for Protein Design (IPD), led by 2024 Nobel Laureate David Baker, researchers are programming proteins to execute specific, highly customized tasks that do not exist in nature.79

Through initiatives like the "Programmable Small Molecule Biosynthesis" project, scientists are redesigning nature's molecular assembly lines, streamlining and recombining biological components to produce entirely new therapeutic materials.79 This platform technology allows for the creation of universally applicable intelligent nanocarriers for theranostics, balancing therapeutic performance with safety.14 These AI-engineered proteins can provide precise disease diagnosis, targeted drug delivery, and continuous treatment monitoring, adapting dynamically to the physiological environment and minimizing off-target effects.14

In Silico Pharmacology and Virtual Populations

A critical historical barrier to universal medicine has been the failure of late-stage clinical trials to accurately reflect the diversity of human populations.13 Traditional Phase III Randomized Controlled Trials (RCTs) are fundamentally inefficient, often excluding specific demographics such as pediatric patients, pregnant women, and the elderly.13

To ensure that newly developed universal medicines are truly effective across all human variations, the industry has widely adopted in silico pharmacology.13 Using advanced Artificial Intelligence, researchers employ Physiologically Based Pharmacokinetic (PBPK) modeling and Quantitative Systems Pharmacology/Toxicology (QSP/QST) to construct sophisticated "virtual populations".13 These models simulate drug exposure, safety, and efficacy across diverse demographics without the immediate need for physical trials.13 For example, QST modeling has been successfully utilized to predict drug-induced liver injury (DILI) in postmenopausal women, generating robust safety profiles rapidly.13

These AI-driven virtual models are now recognized as proprietary, licensable intellectual property.13 By combining these models with Causal Machine Learning—utilizing techniques like Targeted Maximum Likelihood Estimation (TMLE) to reduce bias—researchers can establish causality using observational Real-World Evidence (RWE) sourced from electronic health records, insurance claims, and patient registries.13 This integration of RWE and virtual modeling directly addresses the patient diversity problem, ensuring that the concept of a universal medicine applies universally across the human species.13

CRISPR-Cas Systems and Genomic Programmability

No discussion of universal medicine is complete without addressing the ultimate programmable platform: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins.82 Originally evolved as a bacterial immune system to defend against bacteriophages, CRISPR-Cas systems have been repurposed into highly versatile tools for both targeted gene modifications and ultra-sensitive diagnostics.83

Therapeutic Base Editing and Gene Correction

CRISPR therapeutics are rapidly moving through clinical pipelines, offering universal platforms capable of curing severe genetic disorders by directly editing the human genome. Following the historic approval of CASGEVY (exagamglogene autotemcel) for sickle cell disease, companies like CRISPR Therapeutics are expanding global regulatory submissions.84 Furthermore, precise base-editing technologies are achieving unprecedented results. In late 2025, the first clinical trial of base editing was published involving PM359, a therapeutic designed to correct a mutation in the NCF1 gene responsible for chronic granulomatous disease (an autoimmune disorder leaving patients highly susceptible to infections).85 Treatment with PM359 successfully restored the function of the enzyme NADPH oxidase in the patients' immune cells, providing a programmable template for curing diverse monogenic diseases.85

CRISPR Diagnostics for Pandemic Prevention

Beyond therapeutics, CRISPR serves as a universal diagnostic platform crucial for pandemic prevention. Leveraging the inherent trans-cleavage activities of Cas enzymes (such as Cas12 and Cas13), diagnostic platforms like SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) and DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) have been developed.82 These systems combine the precision of target recognition with reporter molecules to achieve ultra-sensitive, field-deployable detection of pathogen-specific nucleic acids.82 By simply altering the short guide RNA sequences, these platforms can be rapidly reprogrammed to detect entirely new viral genomes with high accuracy, enabling immediate diagnostic responses to emerging global health threats before they escalate into pandemics.82

The Decentralized Science (DeSci) Infrastructure and Digital Therapeutics Supply Chain

The realization of a universal medicine requires more than biological and computational breakthroughs; it necessitates a complete restructuring of the scientific funding, publishing, and supply chain infrastructure.13 The pharmaceutical industry currently faces a critical "speed crisis" in R&D.13 The rapid acceleration of AI development has vastly outpaced the slow, analog cycles of traditional academic peer review.13 Consequently, state-of-the-art AI models, codebases, and validated datasets frequently fall into a "knowledge gap," leading to an "invalidation cascade" where crucial methodologies are excluded from the citable scientific record, rendering research non-reproducible and stifling innovation.13

IP-NFTs, DAOs, and the Financialization of R&D

To resolve this institutional failure, a new digital infrastructure stack utilizing blockchain and Decentralized Science (DeSci) has matured by 2026.13 DeSci platforms tackle issues like restricted access to papers and opaque funding decisions by utilizing decentralized ledgers.86 Platforms such as DeSci Publish utilize decentralized storage networks to assign Persistent Identifiers (PIDs) and Digital Object Identifiers (DOIs) to non-traditional research outputs, including raw datasets, algorithms, and AI models, ensuring they remain Findable, Accessible, Interoperable, and Reusable (FAIR) and immune to traditional "link rot".13

More significantly, DeSci resolves the massive funding bottlenecks that plague traditional R&D.13 Platforms like Molecule and VitaDAO have pioneered the concept of Intellectual Property Non-Fungible Tokens (IP-NFTs).13 By tokenizing the intellectual property associated with a novel therapeutic, in silico model, or dataset, researchers can transform illiquid IP into a tradable, liquid asset.13 This allows Decentralized Autonomous Organizations (DAOs) to crowdfund, govern, and advance early-stage research without relying exclusively on slow institutional grants or highly risk-averse traditional venture capital.13 The convergence of crypto-native capital (e.g., Binance Labs) and incumbent pharmaceutical venture arms (e.g., Pfizer Ventures) funding BioDAOs represents a fundamental financialization of R&D, providing a highly agile pipeline for universal therapeutics.13 Furthermore, blockchain frameworks are being integrated into clinical trial management, establishing immutable audit trails for trial data and decentralized patient recruitment mechanisms.89

Gibson Assembly and Automated Biotechnology

The physical manipulation of biology is also accelerating to match the speed of digital infrastructure. In the UK and globally, the widespread adoption of the Gibson Assembly method has revolutionized synthetic biology.90 Gibson Assembly utilizes a "one-pot" mix of three enzymes—an exonuclease, a polymerase, and a ligase—to seamlessly stitch together multiple DNA fragments efficiently and without leaving unwanted scars in the sequence.90 According to the UK Synthetic Biology Research Centre, the integration of automated Gibson Assembly workstations slashed drug discovery timelines by forty percent in recent years, serving as the biological "compiler" equivalent for the programmable biology era.90

Digital MRV and the Universal Supply Chain

The production of next-generation biologics and their necessary feedstocks requires highly controlled, verified supply chains. In the agricultural cultivation of essential biological materials (e.g., sustainable excipients or plant-based precursors), there is a mandate for resource efficiency. High-tech Controlled Environment Agriculture (CEA) relies heavily on AI-driven autonomous control of climate and lighting, supported by data from advanced deep-learning vision systems like YOLOv8 for stress and disease detection.13

To verify the sustainability and safety of these bio-economic inputs, traditional manual audits have been replaced by Digital Measurement, Reporting, and Verification (dMRV) systems.13 Streaming data from IoT sensors is processed through self-executing smart contracts, providing real-time, programmable trust.13 If a production batch meets stringent, ISO-compliant Life Cycle Assessment (LCA) standards (such as verified carbon-negative footprints achieved via agrivoltaic energy integration), the smart contract automatically issues a tokenized certification or ESG asset.13 This continuous, data-driven verification ensures that the global supply chain for universal medicines is not only robust and highly pure but verifiably sustainable, a critical requirement as global markets enforce stricter environmental regulations.13

The Global Compliance Gauntlet: Regulatory Harmonization and Economic Barriers

The ultimate barrier to deploying a universal medicine is not scientific, but regulatory. The "Global Compliance Gauntlet" represents a fractured, duplicative, and often contradictory web of international regulations that bifurcates markets and delays patient access to life-saving innovations.13 For instance, frameworks vary drastically from strict hospital-pharmacy-only medical models for specific compounds (e.g., Spain's Royal Decree 903/2025) to heavily formalized EU-GMP export hubs (e.g., Malta), requiring immense administrative overhead for cross-border distribution.13

Furthermore, geopolitical pressures and economic realities heavily influence global medicine production. Following policies implemented under the U.S. administration, significant tariffs on branded drug imports have forced pharmaceutical companies to localize production, leading to hundreds of billions in investments reshoring manufacturing to the U.S. and destabilizing European innovation capacities.91 Domestically, ongoing legal battles regarding the 340B ceiling price and Medicare Part D rebate models continue to create uncertainty for drug pricing and distribution.93 Additionally, the industry faces a critical "biosimilar void"; of the 118 biologics expected to lose patent protection between 2025 and 2034, approximately ninety percent have no publicly disclosed biosimilars in development due to high development costs and patent thicket litigation, threatening the affordable distribution of complex therapeutics.94

Technological Gateways and Regulatory Convergence (ICH M13)

To navigate these digital and regulatory borders, the industry employs Reg-Tech "Global Compliance Gateways." These software platforms act as translation layers, automatically converting internal manufacturing data and chain-of-custody logs to meet the disparate requirements of localized track-and-trace systems versus stringent international GMP standards.13 Concurrently, life sciences companies must adapt to the FDA's Quality Management System Regulation (QMSR) alignment, which harmonizes baseline quality requirements for medical devices (including AI capabilities) with international standards, streamlining global compliance programs.94

Simultaneously, international bodies are aggressively pursuing regulatory convergence. The International Council for Harmonisation (ICH) plays a pivotal role in aligning technical requirements to reduce unnecessary duplication of clinical testing.20 Specifically, the implementation of the ICH M13A guideline (which came into legal effect in the EU in January 2025) and the advancement of the M13B guideline standardize the scientific and technical requirements for demonstrating bioequivalence (BE) for immediate-release solid oral dosage forms.99 By establishing internationally harmonized criteria—including provisions for additional strength biowaivers—the ICH enables pharmaceutical developers to generate a single data set acceptable across multiple regions, lowering R&D costs and dramatically accelerating the global authorization of generic and universal therapeutics.97 In the U.S., the FDA is also modernizing its approval process, indicating that one adequate and well-controlled study, along with confirmatory evidence, will increasingly serve as the standard basis for marketing authorization, reducing the need for repetitive testing.102

The Geopolitics of Universal Medicine: The WHO Pandemic Agreement and PABS Annex

The geopolitical necessity for a universal medicine is inextricably linked to the demand for global health equity, a vulnerability starkly exposed during the COVID-19 pandemic when developing nations faced severe delays in access to medical countermeasures.103 In response, the World Health Assembly adopted the WHO Pandemic Agreement on May 20, 2025, a legally binding instrument intended to ensure collaborative preparation, equitable access, and coordinated funding for future infectious disease threats.19

However, the operational core of this treaty—governing the actual distribution of universal vaccines and broad-spectrum medicines—lies within Article 12, which establishes the Pathogen Access and Benefit-Sharing (PABS) System.19 The PABS framework operates on two interconnected pillars: the rapid, obligatory sharing of pathogen materials and genetic sequence data by Member States, and, on an equal footing, the fair, equitable, and rapid sharing of the resulting benefits.21 These benefits explicitly include vaccines, therapeutics, diagnostics, and annual monetary contributions from the commercial utilization of the shared data.21

As of April 2026, the final text of the PABS Annex remains the subject of intense geopolitical negotiation.19 Because the overarching Pandemic Agreement cannot be opened for signature and ratification until the Annex is adopted, the Intergovernmental Working Group (IGWG) extended negotiations into late April 2026 to resolve critical disputes ahead of the Seventy-ninth World Health Assembly.21 Developing nations, particularly under the coordinated diplomacy of the African Union and Africa CDC, are leveraging their early scientific contributions and expanding manufacturing capacities to demand standardized contracts, mandatory technology transfers, and strict compliance mechanisms.104 They insist that access to pathogen data must be contractually tied to enforceable benefit-sharing from participating commercial manufacturers, preventing a repeat of past inequities.104 The successful adoption of the PABS Annex in May 2026 will be the decisive factor in whether universal medical innovations are equitably distributed worldwide, or if they remain constrained by sovereign borders and socioeconomic disparities.19

Conclusion

The creation of a global universal medicine is no longer an insurmountable biological fantasy; it is an active, heavily capitalized engineering objective in 2026. The evidence synthesized in this exhaustive report demonstrates that the scientific community has abandoned the search for a singular, static chemical "panacea." Instead, universal medicine is defined by dynamic, highly adaptable platform technologies capable of broad-spectrum application.

Biological breakthroughs, such as intranasal vaccines utilizing TLR agonists to maintain persistent innate immune activation, provide sweeping protection against an unprecedented array of viral, bacterial, and allergenic threats, demonstrating that immunological memory can be fundamentally reprogrammed.6 Concurrently, Host-Directed Therapies (HDTs) and apoptosis-inducing antivirals like DRACO circumvent the evolutionary arms race of pathogen mutation, while universal antivenoms and broad-spectrum monoclonal antibodies provide highly potent passive prophylaxis.15 In oncology, the integration of mRNA vaccines with immune checkpoint inhibitors, alongside advanced initiatives like ARPA-H's 1-CURE utilizing FLASH radiotherapy and smart biomaterials, promises to standardize treatment across highly heterogeneous cancer types.68

However, these biological components represent only a fraction of the solution. The feasibility of universal medicine is entirely dependent on an integrated digital infrastructure. Multi-Target Drug Discovery powered by deep generative AI models solves the complexities of compound promiscuity 18, while in silico virtual populations eradicate the diversity gaps inherent in traditional clinical trials.13 Reprogrammable genomic tools like CRISPR-Cas provide universal platforms for both therapeutic base editing and ultra-sensitive diagnostics.82 Furthermore, Decentralized Science (DeSci) frameworks, IP-NFTs, and automated systems like Gibson Assembly are democratizing the capital necessary to accelerate these pipelines, bypassing outdated institutional publishing and funding bottlenecks.13

Ultimately, the successful deployment of a universal medicine will not be decided solely in a laboratory or server farm, but at the negotiating table. The success of global harmonization efforts like ICH M13, domestic regulatory alignments, and the enforcement of equitable global distribution through the WHO Pandemic Agreement's PABS Annex will determine if these revolutionary platforms fulfill their potential.21 The convergence of these biological, computational, and regulatory frameworks confirms that the architecture for a global universal medicine is actively being built, heralding a new era of proactive and equitable global health.

Works cited

1. Panacea (medicine) - Wikipedia, accessed April 9, 2026, https://en.wikipedia.org/wiki/Panacea_(medicine)

2. Full text of "A treatise on chemistry" - Internet Archive, accessed April 9, 2026, http://archive.org/stream/atreatiseonchem06schogoog/atreatiseonchem06schogoog_djvu.txt

3. Personalized medicine: the future is here - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11157250/

4. Precision Medicine—Are We There Yet? A Narrative Review of Precision Medicine's Applicability in Primary Care - MDPI, accessed April 9, 2026, https://www.mdpi.com/2075-4426/14/4/418

5. Emerging Health Innovations In 2026 - Personalized Medicine And Precision Care - North American Community Hub - NCHStats, accessed April 9, 2026, https://nchstats.com/health-innovations-personalized-medicine/

6. One vaccine may provide broad protection against many respiratory ..., accessed April 9, 2026, https://med.stanford.edu/news/all-news/2026/02/universal-vaccine.html

7. Publication: Panacea: Making the World's Biomedical Information Computable to Develop Data Platforms for Machine Learning - Harvard DASH, accessed April 9, 2026, https://dash.harvard.edu/entities/publication/c8b9c973-24f6-4008-abce-4139e5bd53bf

8. Why 2026 could mark turning point for medicine. Four key questions - EU Perspectives, accessed April 9, 2026, https://euperspectives.eu/2026/01/2026-clinical-trials/

9. Universal Medicine - Wikipedia, accessed April 9, 2026, https://en.wikipedia.org/wiki/Universal_Medicine

10. Serge Benhayon Universal Medicine defamation case defence - O'Brien Solicitors, accessed April 9, 2026, https://obriensolicitors.com.au/rockett-launch-towards-universal-medicine/

11. Re S (Parental Alienation: Cult) - Courts and Tribunals Judiciary, accessed April 9, 2026, https://www.judiciary.uk/wp-content/uploads/2022/07/re-s-a-child-judgment290420-1.pdf

12. Father Issues Petition to Family Court to Rescue Daughter from Cult, accessed April 9, 2026, https://www.henriquesgriffiths.com/site/blog/hq-blog/father-issues-petition-to-rescue-daughter-from-cult

13. The New Infrastructure_ Synthesizing AI, DeSci, and dMRV for the Next Generation of Regulated Bio-Economies.pdf

14. Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12887271/

15. Future applications of host direct therapies for infectious disease treatment - PubMed, accessed April 9, 2026, https://pubmed.ncbi.nlm.nih.gov/39411713/

16. From desired futures to market realities: examining policy imaginaries and strategies in the globalization of Ayurveda - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/journals/human-dynamics/articles/10.3389/fhumd.2025.1549341/full

17. Double-stranded RNA activated caspase oligomerizer - Wikipedia, accessed April 9, 2026, https://en.wikipedia.org/wiki/Double-stranded_RNA_activated_caspase_oligomerizer

18. Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework - MDPI, accessed April 9, 2026, https://www.mdpi.com/1422-0067/26/23/11443

19. Pandemic prevention, preparedness and response agreement, accessed April 9, 2026, https://www.who.int/news-room/questions-and-answers/item/pandemic-prevention--preparedness-and-response-accord

20. International Regulatory Harmonization - FDA, accessed April 9, 2026, https://www.fda.gov/drugs/cder-international-program/international-regulatory-harmonization

21. WHO Member States agree to extend negotiations on key annex to the Pandemic Agreement, accessed April 9, 2026, https://www.who.int/news/item/28-03-2026-who-member-states-agree-to-extend-negotiations-on-key-annex-to-the-pandemic-agreement

22. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4585027/

23. First new antibiotic in 50 years moves to human trials | iiCON, accessed April 9, 2026, https://www.infectioninnovation.com/first-new-antibiotic-in-50-years-moves-to-human-trials/

24. Multi-Target Drug Discovery: An Opportunity for Novel and Repurposed Bioactive Compounds - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/research-topics/70779/multi-target-drug-discovery-an-opportunity-for-novel-and-repurposed-bioactive-compounds

25. Exploring Compound Promiscuity Patterns and Multi-Target Activity Spaces - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3962225/

26. Contributions of Molecular Properties to Drug Promiscuity | Journal of Medicinal Chemistry, accessed April 9, 2026, https://pubs.acs.org/doi/10.1021/jm301514n

27. Drug discovery: Predicting promiscuity - New York Stem Cell Foundation, accessed April 9, 2026, https://www.nyscf.org/resources/drug-discovery-predicting-promiscuity/

28. High Impact: The Role of Promiscuous Binding Sites in Polypharmacology - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6680532/

29. Drug promiscuity: problems and promises - bioRxiv, accessed April 9, 2026, https://www.biorxiv.org/content/10.1101/2023.12.29.573633v1.full-text

30. Broad-Spectrum Antiviral Therapeutics - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3144912/

31. An Update on Kimer Med, Improving on the DRACO Antiviral Technology and Moving Towards the Clinic - Fight Aging!, accessed April 9, 2026, https://www.fightaging.org/archives/2024/02/an-update-on-kimer-med-improving-on-the-draco-antiviral-technology-and-moving-towards-the-clinic/

32. Kimer Med inks contract with Battelle Memorial Institute to discover & develop new antiviral drug candidates to treat alphaviruses - Pharmabiz.com, accessed April 9, 2026, https://www.pharmabiz.com/NewsDetails.aspx?aid=166891&sid=2

33. Kimer Med, accessed April 9, 2026, https://www.kimermed.co.nz/

34. Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling - PubMed, accessed April 9, 2026, https://pubmed.ncbi.nlm.nih.gov/41650963/

35. Progress toward a broad-spectrum antiviral | National Institutes of Health (NIH), accessed April 9, 2026, https://www.nih.gov/news-events/nih-research-matters/progress-toward-broad-spectrum-antiviral

36. New research makes first broad-spectrum antiviral | EurekAlert!, accessed April 9, 2026, https://www.eurekalert.org/news-releases/1095564

37. Host Directed Therapeutic Strategies to Combat Infection and Reduce Emergence of Drug Resistance Conference, accessed April 9, 2026, https://fusion-conferences.com/conference/53

38. Future applications of host direct therapies for infectious disease treatment - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11473292/

39. Combinatorial and Host-Directed Therapies Against Intracellular Bacterial Pathogens, accessed April 9, 2026, https://www.frontiersin.org/research-topics/77761/combinatorial-and-host-directed-therapies-against-intracellular-bacterial-pathogens

40. Future applications of host direct therapies for infectious disease treatment - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1436557/full

41. Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection - MDPI, accessed April 9, 2026, https://www.mdpi.com/2076-2607/13/5/1040

42. Novel Interventions Targeting Placental and Gut Inflammation to Improve Fetal Growth, accessed April 9, 2026, https://gcgh.grandchallenges.org/challenge/novel-interventions-targeting-placental-and-gut-inflammation-improve-fetal-growth

43. Better Than Penicillin - UConn Today - University of Connecticut, accessed April 9, 2026, https://today.uconn.edu/2026/02/better-than-penicillin/

44. Report highlights 'spots of progress' in a challenging landscape for new antibiotics, accessed April 9, 2026, https://www.cidrap.umn.edu/antimicrobial-stewardship/report-highlights-spots-progress-challenging-landscape-new-antibiotics

45. £3m new funding for breakthrough research to transform antibiotic discovery | Imperial News, accessed April 9, 2026, https://www.imperial.ac.uk/news/articles/2026/3m-funding-for-breakthrough-research-to-transform-antibiotic-discovery-/

46. We're a step closer to having a universal antivenom for snake bites – new study, accessed April 9, 2026, https://www.gavi.org/vaccineswork/were-step-closer-having-universal-antivenom-snake-bites-new-study

47. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins - PubMed, accessed April 9, 2026, https://pubmed.ncbi.nlm.nih.gov/38381847/

48. The Venom Vanquisher - Scripps Research Magazine, accessed April 9, 2026, https://magazine.scripps.edu/features/2025/winter/the-venom-vanquisher/

49. Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles, accessed April 9, 2026, https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-revolution-program-progress-and-advancement

50. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1162342/full

51. A promising new antibody treatment for a neglected respiratory virus - Fred Hutch, accessed April 9, 2026, https://www.fredhutch.org/en/news/spotlight/2026/03/vidd-harris-natcommun.html

52. Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia | ScienceDaily, accessed April 9, 2026, https://www.sciencedaily.com/releases/2026/02/260222092258.htm

53. Universal Vaccine Blocks Viruses, Bacteria, And Allergies With a Nasal Spray : ScienceAlert, accessed April 9, 2026, https://www.sciencealert.com/universal-vaccine-blocks-viruses-bacteria-and-allergies-with-a-nasal-spray

54. Scientists' Push For a Universal Vaccine Takes a Key Step Forward - Drugs.com MedNews, accessed April 9, 2026, https://www.drugs.com/news/scientists-push-universal-vaccine-takes-key-step-forward-128908.html

55. Universal vaccine to treat colds, flu and COVID developed – and a new study suggests it just might work | The Transmission - UNMC, accessed April 9, 2026, https://www.unmc.edu/healthsecurity/transmission/2026/02/25/universal-vaccine-to-treat-colds-flu-and-covid-developed-and-a-new-study-suggests-it-just-might-work/

56. Researchers Reveal Universal Nasal Spray Vaccine With Broad Respiratory Protection, accessed April 9, 2026, https://www.pharmacytimes.com/view/researchers-reveal-universal-nasal-spray-vaccine-with-broad-respiratory-protection

57. Progress for "Universal" Vaccine & More NextGen Covid Vax News (Update No 38), accessed April 9, 2026, https://absolutelymaybe.plos.org/2026/03/01/progress-for-universal-vaccine-more-nextgen-covid-vax-news-update-no-38/

58. HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses, accessed April 9, 2026, https://www.hhs.gov/press-room/hhs-nih-announces-generation-gold-standard.html

59. HHS and NIH introduce Generation Gold Standard, a universal vaccine platform, accessed April 9, 2026, https://www.bioanalysis-zone.com/hhs-and-nih-introduce-generation-gold-standard-a-universal-vaccine-platform/

60. HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses, accessed April 9, 2026, https://www.nih.gov/news-events/news-releases/hhs-nih-launch-next-generation-universal-vaccine-platform-pandemic-prone-viruses

61. Universal Influenza Vaccine Research | NIAID, accessed April 9, 2026, https://www.niaid.nih.gov/diseases-conditions/universal-influenza-vaccine-research

62. Universal Influenza Vaccine Technology Landscape | CIDRAP - IVR Initiative, accessed April 9, 2026, https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape

63. February 2026 updates to the Universal Influenza Vaccine Technology Landscape, accessed April 9, 2026, https://ivr.cidrap.umn.edu/february-2026-updates-universal-influenza-vaccine-technology-landscape

64. The Feasibility of Developing a Universal SARS-CoV-2 Vaccine - MDPI, accessed April 9, 2026, https://www.mdpi.com/2076-393X/14/3/259

65. Pioneering vaccine tech could pave the way for all-in-one shots against rapidly mutating viruses - CEPI, accessed April 9, 2026, https://cepi.net/pioneering-vaccine-tech-could-pave-way-all-one-shots-against-rapidly-mutating-viruses

66. Leyden Labs Demonstrates Feasibility of Novel Antibody-Based Nasal Spray for Flu Prevention, accessed April 9, 2026, https://leydenlabs.com/20260001-news-item-leyden-labs-antibody-nasal-spray-influenza-study

67. Surprising finding could pave way for universal cancer vaccine - UF News, accessed April 9, 2026, https://news.ufl.edu/2025/07/universal-cancer-vaccine/

68. Surprising finding could pave way for universal cancer vaccine - UF Health, accessed April 9, 2026, https://ufhealth.org/news/2025/surprising-finding-could-pave-way-for-universal-cancer-vaccine

69. Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer | EurekAlert!, accessed April 9, 2026, https://www.eurekalert.org/news-releases/1102605

70. ESMO 2025: Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer, accessed April 9, 2026, https://ecancer.org/en/news/27155-esmo-2025-study-finds-covid-19-mrna-vaccine-sparks-immune-response-to-fight-cancer

71. Cancer Vaccines in 2025: Latest Breakthroughs in mRNA and DNA Immunotherapy, accessed April 9, 2026, https://euromedfoundation.com/cancer-vaccines-in-2025-latest-breakthroughs-in-mrna-and-dna-immunotherapy/

72. Driving the Future of Cancer Vaccines: Key Research Milestones from 2025, accessed April 9, 2026, https://www.uwcvi.org/post/driving-the-future-of-cancer-vaccines-key-research-milestones-from-2025

73. Preventing cancer through vaccination: progress, promise, and key trials | UICC, accessed April 9, 2026, https://www.uicc.org/news-and-updates/news/25-m8-preventing-cancer-through-vaccination-progress/promise/and-key-trials

74. AACR: Targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, AI in cancer diagnosis and more | UCLA Health, accessed April 9, 2026, https://www.uclahealth.org/news/release/aacr-targeted-drug-delivery-colorectal-cancer-covid-19s

75. 1-CURE program to transform cancer care with one low-cost, widely ..., accessed April 9, 2026, https://arpa-h.gov/news-and-events/1-cure-program-transform-cancer-care-one-low-cost-widely-accessible-treatment

76. 10 AI-Native Biotechs to Watch in 2026 - News - BioBuzz, accessed April 9, 2026, https://news.biobuzz.io/2026/03/23/10-ai-native-biotechs-to-watch-in-2026/

77. Medical AI Models Transforming Healthcare | 2026 Guide - Deepgram, accessed April 9, 2026, https://deepgram.com/learn/top-medical-ai-models-2026

78. Decoy Therapeutics Builds Momentum with Accelerating Execution, - GuruFocus, accessed April 9, 2026, https://www.gurufocus.com/news/8784835/decoy-therapeutics-builds-momentum-with-accelerating-execution-entering-a-highly-catalytic-phase-with-a-clearly-defined-path-to-clinical-development-of-its-antiviral-pipeline

79. Reprogramming Nature: UCSF Leads AI-Driven Protein Design Initiative, accessed April 9, 2026, https://pharmacy.ucsf.edu/news/2026/03/reprogramming-nature-ucsf-leads-ai-driven-protein-design-initiative

80. Designing AI-programmable therapeutics with the EDEN family of foundation models, accessed April 9, 2026, https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1.full-text

81. Saving real lives with artificial intelligence | Be Boundless - University of Washington, accessed April 9, 2026, https://www.washington.edu/boundless/ai-powered-medicine/

82. CRISPR-based diagnostics for infectious diseases: mechanisms, advancements and clinical transformation prospects - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1769226/full

83. Could CRISPR Help Prevent the Next Global Pandemic? - News-Medical.Net, accessed April 9, 2026, https://www.news-medical.net/health/Could-CRISPR-Help-Prevent-the-Next-Global-Pandemic.aspx

84. CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones, accessed April 9, 2026, https://ir.crisprtx.com/static-files/d195b0eb-78a3-4d3c-beff-0053d9a8aa27

85. 10 CRISPR Companies to Watch in 2026 - Cure., accessed April 9, 2026, https://wewillcure.com/insights/news/crispr-companies-to-watch

86. What Is DeSci and How Is This Emerging Niche Developing in 2026? - KuCoin, accessed April 9, 2026, https://www.kucoin.com/blog/en-what-is-desci-and-how-is-this-emerging-niche-developing-in-2026

87. Decentralized science (DeSci) - Ethereum.org, accessed April 9, 2026, https://ethereum.org/desci/

88. Unlocking Research Innovation with IP-NFTs: How to Get Started with Decentralized Funding | by VitaDAO, accessed April 9, 2026, https://vitadao.medium.com/unlocking-research-innovation-with-ip-nfts-how-to-get-started-with-decentralized-funding-0584b5b1f111

89. Call for Papers | Blockchain in Healthcare Today, accessed April 9, 2026, https://blockchainhealthcaretoday.com/index.php/journal/call-for-papers

90. UK Biotech Investment 2026: Gibson Assembly, DeSci & Bitget Guide, accessed April 9, 2026, https://www.bitget.com/academy/gibson-assembly-and-cloning-in-biotechnology-and-crypto-comprehensive-2026-guide-united-kingdom

91. What Will Shape Pharma in 2026? Key Innovations and Strategic Moves, accessed April 9, 2026, https://pharma.lactalisingredients.com/2026/01/07/what-will-shape-pharma-in-2026-key-innovations-and-strategic-moves/

92. Navigating the Future: 2026 Life Sciences Regulatory Outlook – Global Strategies for Tackling Escalating Cross-Border Challenges | Insights | Ropes & Gray LLP, accessed April 9, 2026, https://www.ropesgray.com/en/insights/viewpoints/102mfc9/navigating-the-future-2026-life-sciences-regulatory-outlook-global-strategies

93. Top Legal Challenges for the Health Care Industry in 2026 | ArentFox Schiff, accessed April 9, 2026, https://www.afslaw.com/perspectives/health-care-counsel-blog/top-legal-challenges-the-health-care-industry-2026

94. Navigating the 2026 Life Sciences Legal Landscape | ArentFox Schiff, accessed April 9, 2026, https://www.afslaw.com/perspectives/alerts/navigating-the-2026-life-sciences-legal-landscape

95. ICH Official web site : ICH, accessed April 9, 2026, https://www.ich.org/

96. The International Council for Harmonisation (ICH) - IFPMA, accessed April 9, 2026, https://www.ifpma.org/initiatives/the-international-council-for-harmonisation-of-technical-requirements-for-pharmaceuticals-for-human-use-ich/

97. Global and Regional Regulatory Harmonization Initiatives - Regulation and Prequalification, accessed April 9, 2026, https://www.who.int/teams/regulation-prequalification/regulation-and-safety/regulatory-convergence-networks/harmonization

98. Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations - Frontiers, accessed April 9, 2026, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1636269/full

99. ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms, accessed April 9, 2026, https://www.ema.europa.eu/en/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline

100. M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Availability - Federal Register, accessed April 9, 2026, https://www.federalregister.gov/documents/2025/06/02/2025-09900/m13b-bioequivalence-for-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver

101. M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms October 2024 - FDA, accessed April 9, 2026, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms

102. Key Global Regulatory Updates Pharmaceutical Companies Must Prepare for in 2026, accessed April 9, 2026, https://curexbio.com/key-global-regulatory-updates-pharmaceutical-companies-must-prepare-for-in-2026/

103. The Pandemic Agreement - What it is, and what it is not, accessed April 9, 2026, https://cepi.net/pandemic-agreement-what-it-and-what-it-not

104. Africa's Critical Role in Shaping and Implementing the Pandemic Agreement's PABS Annex in an Era of Fragmentation - PMC, accessed April 9, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12989124/

105. WHO Pandemic Agreement - Global - World Health Organization (WHO), accessed April 9, 2026, https://www.who.int/health-topics/who-pandemic-agreement

106. Annex (IGWG Bureau 9 March 2026) WHO Pathogen Access and Benefit-Sharing System (“PABS System”) I. Scope, objectives and us, accessed April 9, 2026, https://healthpolicy-watch.news/wp-content/uploads/2026/03/Draft-PABS-Annex-text-Bureau-version-of-9-March-20262.pdf

107. WHO pandemic agreement - Admin, accessed April 9, 2026, https://www.bag.admin.ch/en/who-pandemic-agreement

108. No equity, no pandemic deal: AHF warns wealthy nations on World Health Day, accessed April 9, 2026, https://www.kbc.co.ke/no-equity-no-pandemic-deal-ahf-warns-wealthy-nations-on-world-health-day/